AGN-241751 in the Treatment of Major Depressive Disorder
Status:
Completed
Trial end date:
2019-08-21
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy at 1 day post initial oral dose of
AGN-241751 compared with placebo in participants with Major Depressive Disorder (MDD).